Urinary tract infections in kidney transplant patients admitted to hospital: A real-life experience

doi:10.5500/wjt.v15.i2.99554

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

(108)

(121)

(0)

(2924)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Transplant. Jun 18, 2025; 15(2): 99554
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.99554

Table 2 Characteristics of urinary tract infections

Items		Value
UTIs, n (%)	cUTIs	22 (71)
	cUTIs and bacteremia	5 (16)
	Urosepsis	4 (13)
Microbiological agents isolated², n (%)	Escherichia coli ESBL¹	10 (32)	Meropenem	6 (19)
	Escherichia coli ESBL¹	10 (32)	Ertapenem	4 (13)
	Klebsiella pneumoniae ESBL¹	6 (19)	Meropenem	4 (13)
	Klebsiella pneumoniae ESBL¹	6 (19)	Ertapenem	2 (6)
	Pseudomonas aeruginosa MDR	4 (13)	Meropenem	4 (13)
	Klebsiella pneumoniae no - ESBL	2 (7)	Piperacillin/tazobactam	2 (7)
	Enterococcus faecium VRE	2 (7)	Daptomycin	2 (7)
	Enterococcus faecium Ampi-S	2 (7)	Piperacillin/tazobactam	1 (3)
	Enterococcus faecium Ampi-S	2 (7)	Amoxicillin/clavulanate	1 (3)
	Klebsiella pneumoniae CRE	1 (3)	Ceftazidime/avibactam	1 (3)
	Escherichia coli no - ESBL	1 (3)	Piperacillin/tazobactam	1 (3)
	Pseudomonas aeruginosa no - MDR	1 (3)	Ciprofloxacin	1 (3)
	Proteus mirabilis ESBL	1 (3)	Meropenem	1 (3)
	Citrobacter farmeri ESBL	1 (3)	Meropenem	1 (3)
Overall targeted antibiotic therapy, n (%)	Meropenem		15 (48)
	Ertapenem		7 (23)
	Piperacillin/tazobactam		4 (13)
	Daptomycin		2 (7)
	Ciprofloxacin		1 (3)
	Amoxicillin/clavulanate		1 (3)
	Ceftazidime/avibactam		1 (3)
Duration of targeted therapy in days, median (IQR)	14 (7-18)
Length of stay in days, median (IQR)	15 (8-20)
Outcome
Alive	31 (100)

¹Also isolated from blood cultures (3 Escherichia coli extended-spectrum beta-lactamases, 2 Klebsiella pneumoniae extended-spectrum beta-lactamases).

²Isolated from urine culture. Ampi-S: Ampicillin-sensitive; CRE: Carbapenem-resistant Enterobacterales; cUTIs: Complicated urinary tract infections; ESBL: Extended-spectrum beta-lactamases; IQR: Interquartile range; MDR: Multidrug-resistant germ; UTIs: Urinary tract infections; VRE: Vancomycin-resistant Enterococci.

Full Size Table

Citation: Pinchera B, Carrano R, Schettino E, D'Agostino A, Trucillo E, Cuccurullo F, Salemi F, Piccione A, Gentile I. Urinary tract infections in kidney transplant patients admitted to hospital: A real-life experience. World J Transplant 2025; 15(2): 99554
URL: https://www.wjgnet.com/2220-3230/full/v15/i2/99554.htm
DOI: https://dx.doi.org/10.5500/wjt.v15.i2.99554

Pinchera B, Carrano R, Schettino E, D'Agostino A, Trucillo E, Cuccurullo F, Salemi F, Piccione A, Gentile I. Urinary tract infections in kidney transplant patients admitted to hospital: A real-life experience. World J Transplant 2025; 15(2): 99554 [PMID: 40535502 DOI: 10.5500/wjt.v15.i2.99554]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.